Key Drivers
- Strong Cash Flow
- Stable Margins
- Premium Valuation
AIAI Summary
STE has evolved from a reliable defensive healthcare compounder into a premium-priced quality operator, so the key takeaway is that the stock now hinges on management converting its North Carolina and specialty-chemistry investments into faster, durable growth—otherwise the current valuation leaves little room for another revenue miss or execution slip.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Stable Margins
- •Premium Valuation
STE combines strong cash generation, stable margins, and moderate leverage, but its premium valuation and intangible-heavy balance sheet limit upside.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance stall
- •Support holding
STE remains in an uptrend over the last month, but momentum has stalled below $239, so a breakout above resistance is needed to confirm the rally.
Moved from the low-$220s to $238.91 on 2026-08-10 before pulling back, showing momentum cooling
Sentiment & News
Key News Insights:
- •Earnings beat
- •Capacity expansion
- •Dividend growth
STERIS delivered a solid Q1 earnings beat with steady revenue growth, lifted its dividend, and announced a major $600 million expansion, though the stock slipped on a modest top-line miss.
The news supports a positive long-term outlook for STERIS, but near-term share performance may remain sensitive to revenue misses despite strong fundamentals
Similar Companies in Healthcare
Other companies in the same sector with AI ratings